Tenaya Therapeutics, Inc. (TNYA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tenaya Therapeutics, Inc. (TNYA) trades at $0.92 with AI Score 15/100 (Grade F). Tenaya Therapeutics, Inc. is a biotechnology company focused on developing therapies for heart disease using gene therapy, cellular regeneration, and precision medicine. Market cap: $153.28M, Sector: Healthcare.
Price live · AI analysis from May 7, 2026TNYA stock analysis for 2026: Analysts have set a consensus price target of $2.00 for Tenaya Therapeutics, Inc., suggesting 117.4% upside from the current price of $0.92. The AI MoonshotScore is 15/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
TNYA: 1/1 perspectives are bearish.
How is this calculated? →Tenaya Therapeutics, Inc. (TNYA) Healthcare & Pipeline Overview
Tenaya Therapeutics, Inc. is a biotechnology firm specializing in gene therapy and cellular regeneration to treat heart diseases. Their focus on genetic cardiomyopathies and heart failure positions them within the competitive biotechnology landscape, targeting significant unmet needs in cardiovascular medicine.
What Is the Investment Thesis for TNYA?
Tenaya Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on gene therapy and precision medicine for heart diseases addresses a significant unmet need. Key value drivers include the successful development and regulatory approval of its lead candidates, TN-201 and TN-301. Upcoming clinical trial results for these programs will be critical catalysts. The company's market capitalization of $153.28M reflects both the potential and the inherent risks associated with early-stage biotechnology companies. A profit margin of -36891.1% indicates substantial ongoing R&D investment. The company's beta of 3.0 suggests high volatility relative to the market. Successful execution of clinical trials and strategic partnerships will be essential for realizing the company's long-term value.
Based on FMP financials and quantitative analysis
TNYA Key Highlights
- Market Cap: $0.13B, reflecting the company's valuation in the biotechnology market.
- Profit Margin: -36891.1%, indicating significant investment in research and development.
- Beta: 3.00, suggesting high volatility compared to the broader market.
- Focus on gene therapy and precision medicine, positioning the company in a high-growth area of biotechnology.
- Pipeline includes multiple programs targeting genetic heart diseases, offering potential for significant clinical impact.
Who Are TNYA's Competitors?
TNYA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.67M | 67 |
| CRSP CRISPR Therapeutics AG | $60.77 | -1.81% | $5.86B | 44 |
| ANAB AnaptysBio, Inc. | $67.29 | +8.00% | $2.90B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $23.12 | +4.69% | $2.05B | 79 |
| ABCL AbCellera Biologics Inc. | $7.69 | -2.29% | $2.35B | 76 |
| CGEN Compugen Ltd. | $2.38 | +1.06% | $225.51M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $24.32 | +4.58% | $1.58B | 68 |
| IVBXF Innovent Biologics, Inc. | $10.15 | -13.05% | $17.61B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TNYA's Key Strengths?
- Innovative gene therapy and cellular regeneration platforms.
- Focus on genetically defined heart diseases.
- Strong intellectual property portfolio.
- Experienced management team.
What Are TNYA's Weaknesses?
- Early-stage clinical development.
- High cash burn rate.
- Reliance on successful clinical trial outcomes.
- Limited commercialization experience.
What Could Drive TNYA Stock Higher?
- Clinical trial results for TN-201 in genetic hypertrophic cardiomyopathy (gHCM).
- Clinical trial results for TN-301 in heart failure with preserved ejection fraction (HFpEF).
- Initiation of clinical trials for TN-401 in genetic arrhythmogenic right ventricular cardiomyopathy (gARVC).
- Advancement of the Reprogramming program for cardiac regeneration through preclinical studies.
- Potential partnerships with larger pharmaceutical companies for commercialization.
What Are the Key Risks for TNYA?
- Financial-distress signal — its Altman Z-Score of -4.60 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-80.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for lead programs.
- Regulatory delays or rejection of marketing applications.
- Competition from other biotechnology companies developing therapies for heart disease.
- High cash burn rate and need for additional financing.
- Changes in the healthcare landscape and reimbursement policies.
What Are the Growth Opportunities for TNYA?
- TN-201 for Genetic Hypertrophic Cardiomyopathy (gHCM): The market for gHCM therapies is substantial, with limited treatment options currently available. TN-201, an AAV-based gene therapy, targets MYBPC3 gene mutations, a common cause of gHCM. Successful clinical trials and regulatory approval could position TN-201 as a leading therapy in this space, potentially capturing a significant share of the market, estimated to reach $1 billion by 2030.
- TN-301 for Heart Failure with Preserved Ejection Fraction (HFpEF) and Genetic Dilated Cardiomyopathy (gDCM): HFpEF is a prevalent and challenging condition with few effective treatments. TN-301, an HDAC6i inhibitor, offers a novel approach to treating HFpEF and gDCM. The market for HFpEF therapies is projected to grow to $15 billion by 2028, presenting a significant opportunity for TN-301 if it demonstrates clinical efficacy and safety.
- TN-401 for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy (gARVC): gARVC, caused by PKP2 gene mutations, is a rare but serious condition. TN-401, an AAV-based gene therapy, aims to address the underlying genetic cause of gARVC. While the market size is smaller compared to HFpEF, the lack of targeted therapies creates an opportunity for TN-401 to become a valuable treatment option.
- DWORF Gene Therapy for Dilated Cardiomyopathy (DCM): Dilated cardiomyopathy (DCM) represents a significant area of unmet need. Tenaya's AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM offers a novel therapeutic approach. If successful, this therapy could address a broad patient population and capture a substantial share of the DCM treatment market.
- Reprogramming Program for Cardiac Regeneration: Tenaya's AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction represents a groundbreaking opportunity. Successful development of this program could revolutionize heart failure treatment by restoring cardiac function. The market for regenerative therapies is projected to grow significantly, offering substantial potential for Tenaya.
What Opportunities Does TNYA Have?
- Partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas within cardiovascular disease.
- Advancement of pipeline programs through clinical trials.
- Potential for breakthrough therapies in areas of unmet need.
What Threats Does TNYA Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other biotechnology companies.
- Changes in the healthcare landscape.
What Are TNYA's Competitive Advantages?
- Proprietary gene therapy platforms.
- Focus on specific genetic mutations in heart disease.
- Strong intellectual property portfolio.
- Expertise in cardiovascular biology and gene therapy.
What Does TNYA Do?
Tenaya Therapeutics, Inc., founded in 2016 and headquartered in South San Francisco, California, is a biotechnology company dedicated to discovering, developing, and delivering innovative therapies for heart disease. The company operates on three core platforms: cellular regeneration, gene therapy, and precision medicine. These platforms drive the development of treatments targeting the underlying causes of heart conditions, particularly those with a genetic basis. Tenaya's pipeline includes several promising candidates, such as TN-201, an adeno-associated virus (AAV)-based gene therapy designed to treat genetic hypertrophic cardiomyopathy (gHCM) caused by mutations in the MYBPC3 gene. Another key program is TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) being developed for heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). Additionally, Tenaya is advancing TN-401, an AAV-based gene therapy for genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by PKP2 gene mutations. The company is also pursuing a DWORF gene therapy for DCM and a Reprogramming program aimed at cardiac regeneration following myocardial infarction. Tenaya's strategic focus on genetically defined heart diseases differentiates it within the competitive biotechnology sector.
What Products and Services Does TNYA Offer?
- Develop gene therapies for genetic heart diseases.
- Utilize cellular regeneration techniques to repair damaged heart tissue.
- Employ precision medicine to target specific genetic mutations.
- Develop treatments for hypertrophic cardiomyopathy (HCM).
- Create therapies for heart failure with preserved ejection fraction (HFpEF).
- Research treatments for arrhythmogenic right ventricular cardiomyopathy (ARVC).
How Does TNYA Make Money?
- Develop proprietary gene therapies and small molecule inhibitors.
- Conduct preclinical and clinical trials to evaluate the safety and efficacy of their therapies.
- Seek regulatory approval from the FDA for their products.
- Potentially partner with larger pharmaceutical companies for commercialization.
What Industry Does TNYA Operate In?
Tenaya Therapeutics operates within the dynamic and competitive biotechnology industry, specifically targeting cardiovascular diseases. The market for heart disease therapies is substantial, driven by the increasing prevalence of conditions like heart failure and genetic cardiomyopathies. The company's focus on gene therapy and precision medicine aligns with the industry's shift towards more targeted and personalized treatments. Competition includes both large pharmaceutical companies with established cardiovascular franchises and smaller biotechnology firms developing novel therapies. Success in this landscape requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships.
Who Are TNYA's Key Customers?
- Patients with genetic heart diseases.
- Cardiologists and other healthcare professionals.
- Hospitals and medical centers.
- Potentially, pharmaceutical companies through licensing agreements.
Tenaya Therapeutics, Inc. (TNYA) Valuation Context
Valued at $153.28M, TNYA is classified as a micro-cap stock. Relative to its peer group, TNYA's quantitative score of 15/100 is below the peer average of 69/100.
ROE -81%Key Financial Metrics
Return on equity for Tenaya Therapeutics, Inc. stands at -80.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -61.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -49.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -69.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Tenaya Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.60 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Tenaya Therapeutics, Inc. revenue of about $10.2M for fiscal 2026, with EPS near $-0.40. The estimate reflects 4 contributing analysts.
TNYA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Tenaya's gene therapy platform is generating buzz; early trial data hints at potential breakthroughs, fueling optimism.
- Recent insider buying suggests management believes the stock is undervalued, boosting investor confidence.
- Despite market volatility, community sentiment remains largely positive, with many seeing Tenaya as a long-term growth play.
- The company is focused on cardiovascular diseases, a massive market with unmet needs, attracting attention from larger pharma.
Bear Case
- The gene therapy space is notoriously risky; clinical trials are unpredictable, and setbacks can be devastating.
- Community sentiment, while positive, shows increasing concern about cash burn and the need for future funding.
- Competition in cardiovascular gene therapy is intensifying, with larger players entering the field, potentially squeezing Tenaya.
- Market perception is heavily reliant on trial outcomes; any negative news could trigger a significant sell-off, similar to what happened with other biotech companies facing trial failures.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TNYA Latest News
-
Earnings Scheduled For May 6, 2026
benzinga · May 6, 2026
TNYA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TNYA.
Price Targets
Consensus target: $2.00
TNYA MoonshotScore
What does this score mean?
The MoonshotScore rates TNYA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Faraz Ali
CEO
Faraz Ali serves as the Chief Executive Officer of Tenaya Therapeutics. His background includes extensive experience in the biotechnology and pharmaceutical industries. Prior to joining Tenaya, he held leadership positions at various companies, focusing on corporate strategy, business development, and commercial operations. His expertise spans across multiple therapeutic areas, including cardiovascular disease. He is responsible for guiding Tenaya's strategic direction and overseeing the company's operations.
Track Record: Under Faraz Ali's leadership, Tenaya Therapeutics has advanced its pipeline of gene therapy and precision medicine programs for heart disease. He has overseen the company's growth, including key milestones in clinical development and strategic partnerships. His focus has been on building a strong team and fostering a culture of innovation to drive the company's mission forward.
Common Questions About TNYA (Healthcare)
What does Tenaya Therapeutics, Inc. do?
Tenaya Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for heart disease. They utilize cellular regeneration, gene therapy, and precision medicine platforms to develop treatments for various heart conditions, particularly those with a genetic basis. Their pipeline includes programs targeting genetic hypertrophic cardiomyopathy (gHCM), heart failure with preserved ejection fraction (HFpEF), and genetic arrhythmogenic right ventricular cardiomyopathy (gARVC), among others. The company aims to address significant unmet needs in cardiovascular medicine through innovative therapeutic approaches.
What do analysts say about TNYA stock?
Analyst coverage of Tenaya Therapeutics, Inc. (TNYA) reflects the inherent risks and potential rewards associated with early-stage biotechnology companies. Key valuation metrics and growth considerations often revolve around the progress of their clinical trials, particularly for lead candidates like TN-201 and TN-301. Analyst consensus typically incorporates expectations for regulatory approvals, market potential, and competitive landscape. However, due to the high-risk nature of biotechnology investments, analyst ratings and price targets can be highly variable and subject to change based on clinical trial outcomes and regulatory developments.
What are the main risks for TNYA?
Tenaya Therapeutics, Inc. faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the efficacy and safety of their therapies must be demonstrated through rigorous testing. Regulatory hurdles and potential delays in obtaining marketing approvals from the FDA also pose a threat. Competition from other biotechnology companies developing similar therapies could impact market share. Additionally, the company's high cash burn rate and reliance on future financing to fund ongoing research and development activities present financial risks.
What are the key factors to evaluate for TNYA?
Tenaya Therapeutics, Inc. (TNYA) holds an AI score of 15/100 (low). Analysts target $2.00 (+117%). Not financial advice.
How frequently does TNYA data refresh on this page?
TNYA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TNYA's recent stock price performance?
Tenaya Therapeutics, Inc. (TNYA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative gene therapy and cellular regeneration platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TNYA overvalued or undervalued right now?
Valuing Tenaya Therapeutics, Inc. (TNYA) requires multiple metrics. Analysts target $2.00 (+117%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TNYA?
Before investing in Tenaya Therapeutics, Inc. (TNYA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.